| Chemotherapy | Chemoradiotherapy | ||||
---|---|---|---|---|---|---|
Characteristics | All patients | Cis/ 5-Fu | Doc/ 5-Fu | Radio alone | Cis/ 5-Fu/ Radio | Doc/ 5-Fu/ Radio |
Patients, No. (%) | 145 (100) | 35 (24.1) | 38 (26.2) | 12 (8.3) | 30 (20.7) | 30 (20.7) |
Age, y median (range) | 62 (44-84) | 60 (48-81) | 61 (45-78) | 68 (44-83) | 63 (45-74) | 61 (52-84) |
Sex (%) | Â | Â | Â | Â | Â | Â |
Males | 92 (63.4) | 25 (27.2) | 24 (26.1) | 6 (6.5) | 19 (20.6) | 18 (19.6) |
Females | 53 (36.6) | 10 (18.9) | 14 (26.4) | 6 (11.3) | 11 (20.8) | 12 (22.6) |
ECOG, PS (%) | Â | Â | Â | Â | Â | Â |
0-1 | 133 (91.7) | 32 (24.1) | 34 (25.6) | 12 (9.0) | 27 (20.3) | 28 (21.0) |
2 | 12 (8.3) | 3 (25.0) | 4 (33.3) | 0 (0.0) | 3 (25.0) | 2 (16.7) |
TNM stage (%) | Â | Â | Â | Â | Â | Â |
II | 28 (19.3) | 0 (0.0) | 0 (0.0) | 12 (42.9) | 15 (53.6) | 1 (3.5) |
III | 47 (32.4) | 2 (4.2) | 1 (2.1) | 0 (0.0) | 15 (31.9) | 29 (61.7) |
IV | 70 (48.2) | 33 (47.1) | 37 (52.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
G stage (%) | Â | Â | Â | Â | Â | Â |
G1 | 20 (13.8) | 4 (20.0) | 3 (15.0) | 8 (40.0) | 3 (15.0) | 2 (10.0) |
G2 | 90 (62.1) | 25 (27.7) | 24 (26.7) | 3 (3.3) | 24 (26.7) | 14 (15.6) |
G3 | 35 (24.1) | 6 (17.1) | 11 (31.4) | 1 (2.9) | 3 (8.6) | 14 (40.0) |
JWA median (range) | 2.4(0.0002-126.0) | 3(0.001-29.1) | 2.2(0.0002-126.0) | 3.9(0.3-67.8) | 3.2(0.0014-50.1) | 2.5(0.001-34.8) |
XRCC1 median (range) | 8.6(0.03-1410.4) | 11.3(0.04-190.7) | 5.5(0.03-211.7) | 11.9(0.9-327.6) | 9(0.1-1410.4) | 7.3(0.03-64.3) |
BRCA1 median (range) | 11.4(0.4–70.0) | 10.2(0.4–70.0) | 10.9(0.6–44.9) | 10.3(0.4–44.2) | 11.4(1.2-62.9) | 12.2(2.0–58.9) |
Response rate (CR + PR), No. (%) | 50 (68.5) | 60 (83.3) | ||||
Median OS (months, 95%CI) | 13 (11.3-14.7) | 13.5 (11.3-15.7) |